Partial
Significantly Misaligned
Patient Risk:
High
Summary
Most prescribing-info facts (strengths, indications for IBS-C adults and CIC adults, GC-C agonist mechanism, common adverse reactions, pediatric contraindication under 2 years, and trial-supported efficacy directions) are supported by the provided label excerpts; however, there are multiple material dosing and safety mismatches (incorrect adult IBS-C starting dose, incorrect comparison dosing statement for CIC, and an apparent pediatric contraindication misstatement for under 6 years).
Category Scores
Accurate Statements
Linzess is available in capsule strengths of 75 mcg, 150 mcg, and 225 mcg.
Unsupported as stated: label excerpts list 72 mcg, 145 mcg, and 290 mcg capsules (DESCRIPTION, strengths list).
Linzess is used to treat irritable bowel syndrome with constipation (IBS-C).
Supported: INDICATIONS AND USAGE includes IBS-C in adults and pediatric patients 7 years of age and older.
Linzess is used to treat chronic idiopathic constipation (CIC).
Supported: INDICATIONS AND USAGE includes CIC in adults.
Linzess is a guanylate cyclase-C (GC-C) agonist.
Supported: DESCRIPTION and CLINICAL PHARMACOLOGY (12.1).
Linzess works by increasing fluid secretion in the intestines.
Supported in substance: CLINICAL PHARMACOLOGY (12.1) describes increased intestinal fluid via cGMP-mediated chloride/bicarbonate secretion and increased intestinal fluid and accelerated transit.
Clinical trials have demonstrated that Linzess improves bowel movement frequency and consistency in patients with IBS-C and CIC.
Supported: CLINICAL STUDIES 14.1 and 14.3 state improvements vs placebo in stool/CSBM frequency and stool consistency (BSFS).
Clinical trials have demonstrated that Linzess reduces abdominal pain in patients with IBS-C and CIC.
Partially supported: CLINICAL STUDIES 14.1 supports abdominal pain reduction in IBS-C. The provided excerpts for CIC (14.3) do not explicitly state abdominal pain reduction; they describe CSBM and related constipation endpoints.
The most common side effect reported with Linzess is diarrhea.
Supported: ADVERSE REACTIONS (6.1) states diarrhea was the most commonly reported adverse reaction in IBS-C pivotal trials and in CIC placebo-controlled studies.
Other potential side effects of Linzess include abdominal pain.
Supported: ADVERSE REACTIONS tables list abdominal pain in at least 2% of patients (IBS-C Table 1; CIC Table 2) and also note it as a common discontinuation reason.
Other potential side effects of Linzess include flatulence.
Supported: ADVERSE REACTIONS tables list flatulence in IBS-C Table 1 and CIC Table 2.
Linzess is co-developed and co-marketed by Ironwood Pharmaceuticals and AbbVie.
Unsupported: No such information appears in the provided label excerpts.
Linzess reduces visceral sensitivity.
Supported only in indirect/animal-model wording: CLINICAL PHARMACOLOGY (12.1) mentions in animal models reduced intestinal pain; it does not use the term 'visceral sensitivity' in the provided excerpts.
Reduced visceral sensitivity may contribute to reduced abdominal pain.
Unsupported: The provided excerpts do not state this causal relationship using that phrasing.
Increasing fluid secretion in the intestines helps soften stool and stimulate bowel movements.
Partially supported: CLINICAL PHARMACOLOGY describes increased intestinal fluid and accelerated transit; CLINICAL STUDIES describe improved stool frequency/consistency. The specific wording 'soften stool' and 'stimulate bowel movements' is not explicitly stated in the provided excerpts.
For IBS-C and CIC in adults, dosage adjustments may be made to utilize the 75 mcg or 225 mcg strengths.
Unsupported: Label excerpts specify IBS-C adults: 290 mcg once daily; 72 mcg once daily may be used based on presentation/tolerability (for IBS-C adults). CIC adults: 145 mcg once daily with a 72 mcg dose available; no 75 mcg or 225 mcg strengths are present in the provided excerpts.
For IBS-C in adults, the recommended starting dose of Linzess is typically 145 mcg once daily.
Contradiction: IBS-C adults recommended dosage is 290 mcg once daily (2.1).
For CIC in adults, the recommended starting dose of Linzess is also generally 145 mcg once daily.
Supported: CIC recommended dosage in adults is 145 mcg orally once daily (2.1).
Linzess is contraindicated in children under six years of age due to the risk of severe diarrhea that can lead to dehydration.
Contradiction: Contraindication is patients less than 2 years of age due to risk of serious dehydration (4 and 8.4).
Linzess is not recommended for use in pediatric patients.
Contradiction/Unsupported: Label indicates approved pediatric use for IBS-C (>=7 years) and FC (>=2 years) and states safety/effectiveness for those indications; it is not 'not recommended' for pediatric patients overall.
Unsupported Statements
Linzess is available in capsule strengths of 75 mcg, 150 mcg, and 225 mcg.
Provided label excerpts list 72 mcg, 145 mcg, and 290 mcg capsules for oral administration; 75/150/225 mcg are not supported.
Linzess is co-developed and co-marketed by Ironwood Pharmaceuticals and AbbVie.
No such co-development/co-marketing statement appears in the provided label excerpts.
Linzess reduces visceral sensitivity.
The provided excerpt uses 'reduce intestinal pain' in animal models, but does not explicitly state 'visceral sensitivity' in the shown text.
Reduced visceral sensitivity may contribute to reduced abdominal pain.
Not stated in the provided excerpts as a causal mechanism.
Increasing fluid secretion in the intestines helps soften stool and stimulate bowel movements.
While the label supports increased intestinal fluid and accelerated transit, and clinical studies support improved stool consistency/frequency, the specific statement about 'soften stool'/'stimulate bowel movements' is not explicitly supported verbatim.
Clinical trials have demonstrated that Linzess reduces abdominal pain in patients with IBS-C and CIC.
IBS-C abdominal pain reduction is supported; the provided CIC excerpt focuses on constipation endpoints and does not explicitly claim abdominal pain reduction.
Contradictions
High
AI Statement
For IBS-C in adults, the recommended starting dose of Linzess is typically 145 mcg once daily.
Label Reference
2.1 Recommended Dosage (IBS-C): Adults: 290 mcg orally once daily; also notes 72 mcg once daily may be used based on individual presentation/tolerability.
Low
AI Statement
For CIC in adults, the recommended starting dose of Linzess is also generally 145 mcg once daily.
Label Reference
2.1 Recommended Dosage (CIC in Adults): The recommended dosage is 145 mcg orally once daily (a 72 mcg once daily dosage may be used...).
High
AI Statement
For IBS-C and CIC in adults, dosage adjustments may be made to utilize the 75 mcg or 225 mcg strengths.
Label Reference
2.1 and DESCRIPTION list available strengths as 72, 145, 290 mcg; dosing adjustments described include 72 mcg once daily may be used for IBS-C adults and a 72 mcg dose is evaluated/available for CIC in adults.
High
AI Statement
Linzess is contraindicated in children under six years of age due to the risk of severe diarrhea that can lead to dehydration.
Label Reference
4 CONTRAINDICATIONS and 8.4 Pediatric Use: contraindicated in patients less than 2 years of age due to risk of serious dehydration (not under 6 years; not described as severe diarrhea specifically in the provided contraindication text).
High
AI Statement
Linzess is not recommended for use in pediatric patients.
Label Reference
1 INDICATIONS AND USAGE includes IBS-C in pediatric patients 7 years and older and FC in pediatric patients 2 years and older; 8.4 states safety/effectiveness established for those pediatric indications.
Important Omissions
For IBS-C adults, label specifies recommended dosage 290 mcg once daily and that 72 mcg once daily may be used based on individual presentation or tolerability; the AI did not mention these specifics (and instead stated 145 mcg).
Importance:
High
For CIC adults, label also specifies a 72 mcg once daily dose may be used based on individual presentation or tolerability; the AI did not mention this adjustment.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Contradictory pediatric contraindication age (<6 years vs <2 years) and incorrect IBS-C adult starting dose (145 mcg vs 290 mcg) could materially mislead dosing/safety interpretation. Additional strength/adjustment mismatches (75/225 vs 72/290) further increase risk of dosing error.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Significantly Misaligned
Primary Issue
Incorrect adult IBS-C dosing and incorrect pediatric contraindication statement, plus incorrect strength values and erroneous strength-adjustment claims.
Suggested Improvement
Use label-listed strengths (72/145/290 mcg), state IBS-C adult recommended dosage as 290 mcg once daily (with possible 72 mcg based on tolerability/presentation), state pediatric contraindication as <2 years, and avoid blanket 'not recommended in pediatric patients' language.